Publication date: Oct 09, 2018
Introduction HIV/AIDS, tuberculosis, and malaria are responsible for most human deaths produced by infectious diseases worldwide. Vaccination against HIV requires generation of memory T cells and neutralizing antibodies, mucosal immunity, and stimulation of an innate immune responses. In this context, the use of Mycobacterium bovis BCG as a live vaccine vehicle is a promising approach for T-cell induction. Areas covered In this review, we provide a comprehensive summary of the literature regarding immunogenicity studies in animal models performed since 2005. Furthermore, we provide expert commentary and five-year view on how the development of potential recombinant BCG based HIV vaccines involves careful selection of the HIV antigen, expression vectors, promoters, BCG strain, preclinical animal models, influence of pre-existing immunity and safety issues, for the rational design of recombinant BCG:HIV vaccines to prevent HIV transmission in the general population. Expert Commentary The three critical issues to be considered when developing a rBCG:HIV vaccine are codon optimization, antigen localization, and plasmid stability in vivo. The use of integrative expression vectors are likely to improve the mycobacterial vaccine stability and immunogenicity to develop not only recombinant BCG-based vaccines expressing second generation of HIV-1 immunogens but also other major pediatric pathogens to prime protective responses shortly following birth.
Kilpel”ainen, A., Maya-Hoyos, M., Saub’i, N., Soto, C.Y., and Joseph Munne, J. Advances and challenges in recombinant Mycobacterium bovis BCG-based HIV vaccine development: Lessons learned. 00659. 2018 Expert Rev Vaccines.
Please signin to view all article content and metadata.